The company is also developing an assay to identify best responders to the therapy, which may include patients with certain lung, pancreatic, and kidney tumors.
The firm is testing the activity of AN9025 in patients with various solid tumors harboring KRAS, NRAS, or HRAS mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results